In Vivo Application of RNA Interference: From Functional Genomics to Therapeutics

Advances in Genetics

Volumn 54, Issue , 2005, Pages 115-142

  Lu, Patrick Y ^a   Xie, Frank ^a   Woodle, Martin C ^a  

^a Intradigm Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA;

ANIMAL; ANTIBODY SPECIFICITY; DRUG DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENETICS; GENOMICS; HUMAN; IN VITRO STUDY; NEOPLASM; REVIEW; RNA INTERFERENCE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE TARGETING; GENE THERAPY; GENOMICS; HUMANS; NEOPLASMS; ORGAN SPECIFICITY; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 25144498128     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(05)54006-9     Document Type: Review

References (64)

1. Akaneya Y., Jiang B., and Tsumoto T. RNAi-induced gene silencing by local electroporation in targeting brain region. J. Neurophysiol. 93 (2005) 594-602
2. Bantounas I., Phylactou L.A., and Uney J.B. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J. Mol. Endocrinol. 33 (2004) 545-557
3. Buckingham S.D., Esmaeili B., Wood M., and Sattelle D.B. RNA interference: From model organisms towards therapy for neural and neuromuscular disorders. Hum. Mol. Genet. Spec. No 2 (2004) R275-R288
4. Chi J.T., Chang H.Y., Wang N.N., Chang D.S., Dunphy N., and Brown P.O. Genomewide view of gene silencing by small interfering RNAs. Proc. Natl. Acad. Sci. USA 100 (2003) 6364-6369
5. Chien P.Y., Wang J., Carbonaro D., Lei S., Miller B., Sheikh S., Ali S.M., Ahmad M.U., and Ahmad I. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther (2004 Dec 03) (2004)
6. Contreras J.L., Vilatoba M., Eckstein C., Bilbao G., Anthony Thompson J., and Eckhoff D.E. Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery 136 (2004) 390-400
7. Davidson B.L., and Paulson H.L. Molecular medicine for the brain: Silencing of disease genes with RNA interference. Lancet Neurol. 3 3 (2004) 145-149
8. Devroe E., and Silver P.A. Retrovirus-delivered siRNA. BMC Biotechnol. 28 (2002) 15
9. Ding Q., Grammer J.R., Nelson M.A., Guan J.L., Stewart Jr. J.E., and Glodson C.L. p27(Kip1) and cyclin D1 are necessary for focal adhesion kinase (FAK) regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain. J. Biol. Chem. (2004 Nov 19) (2004)
10. Dorn G., Patel S., Wotherspoon G., Hemmings-Mieszczak M., Barclay J., Natt F.J., Martin P., Bevan S., Fox A., Ganju P., Wishart W., and Hall J. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32 (2004) e49
11. Dubey P.K., Mishra V., Jain S., Mahor S., and Vyas S.P. Liposomes modified with cyclic RGD peptide for tumor targeting. J. Drug Target. 12 (2004) 257-264
12. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23 (2004) 1539-1548
13. Filleur S., Courtin A., Ait-Si-Ali S., Guglielmi J., Merle C., Harel-Bellan A., Clezardin P., and Cabon F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 63 (2003) 3919-3922
14. Ganju P., and Hall J. Potential applications of siRNA for pain therapy. Expert Opin Biol Ther. 4 (2004) 531-542
15. Ge Q., Filip L., Bai A., Nguyen T., Eisen H.N., and Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101 (2004) 8676-8681
16. Giladi H., Ketzinel-Gilad M., Rivkin L., Felig Y., Nussbaum O., and Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther. 8 (2004) 769-776
17. Golzio M., Mazzolini L., Moller P., Rols M.P., and Teissie J. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther. (2004 Dec 09) (2004)
18. Hagstrom J.E., Hegge J., Zhang G., Noble M., Budker V., Lewis D.L., Herweijer H., and Wolff J.A. A facile non-viral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol. Ther. 10 2 (2004) 386-398
19. Hassani Z., Lemkine G.F., Erbacher P., Palmier K., Alfama G., Giovannangeli C., Behr J.P., and Demeneix B.A. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. (2004 Oct 28) (2004)
20. Heidel J.D., Hu S., Liu X.F., Triche T.J., and Davis M.E. Lack of interferon response in animals to naked siRNAs. Nature Biotech. 22 (2004) 1579-1582
21. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., and Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
22. Jackson A., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., and Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21 (2003) 635-637
23. Kakizawa Y., Furukawa S., and Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J. Control Release 97 (2004) 345-356
24. Kariko K., Bhuyan P., Capodici J., and Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172 (2004) 6545-6549
25. Khan A., Benboubetra M., Sayyed P.Z., Ng K.W., Fox S., Beck G., Benter I.F., and Akhtar S. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: In vitro and in vivo studies. J. Drug Target. 12 (2004) 393-404
26. Kim B., Tang Q., Biswas P.S., Xu J., Schiffelers R.M., Xie F.Y., Ansari A.M., Scaria P.V., Woodle M.C., Lu P., and Rouse B.T. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165 (2004) 2177-2185
27. Kobayashi N., Matsui Y., Kawase A., Hirata K., Miyagishi M., Taira K., Nishikawa M., and Takakura Y. Vector-based in vivo RNA interference: Dose- and time-dependent suppression of transgene expression. J. Pharmacol. Exp. Ther. 308 (2004) 688-693
28. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., and Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA 10 (2004) 766-771
29. Lewis D.L., Hagstrom J.E., Loomis A.G., Wolff J.A., and Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nature Genet. 32 (2002) 107-108
30. Li B.J., et al. Prophylactic and therapeutic efficacies of siRNA targeting SARS coronavirus in rhesus macaques (2005) Submitted for publication.
31. Lu P.Y., Xie F.Y., and Woodle M.C. Tumor inhibition by RNAi-mediated VEGF and VEGFR2 down regulation in xenograft models. Cancer Gene Ther. 10 Suppl. 1 (2002) 011
32. Lu P.Y., Xie F.Y., Scaria P., and Woodle M.C. From correlation to causation to control: Utilizing preclinical disease models to improve cancer target discovery. Preclinica 1 (2003) 31-42
33. Lu P.Y., Xie F.Y., and Woodle M.C. siRNA-mediated antitumorgenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther. 5 (2003) 225-234
34. Lu P.Y., Xie F.Y., and Woodle M.C. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol. Med. 11 (2005) 104-113
35. Massaro D., Massaro G.D., and Clerch L.B. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 287 (2004) L1066-L1070
36. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., and Kay M.A. RNA interference in adult mice. Nature 418 (2002) 38-39 6893
37. McManus M.T., and Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nature Med. 3 (2002) 737-747
38. Minakuchi Y., Takeshita F., Kosaka N., Sosaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Kato A., Terada M., and Ochiya T. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32 (2004) e109
39. Ogris M., Walker G., Blessing T., Kircheis R., Wolschek M., and Wagner E. Tumor-targeted gene therapy: Strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Controll. Release 91 (2003) 173-181
40. Pardridge W.M. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther. 4 (2004) 1103-1113
41. Pun S.H., Tack F., Bellocq N.C., Cheng J., Grubbs B.H., Jensen G.S., Davis M.E., Brewster M., Janicot M., Janssens B., Floren W., and Bakker A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3 (2004) 641-650
42. Reich S.J., Fosnot J., Kuroki A., Tang W., Yang X., Maguire A.M., Bennett J., and Tolentino M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vision 9 (2003) 210-216
43. Ren T., Zhang G., and Liu D. Synthesis of galactosyl compounds for targeted gene delivery. Bioorg. Med. Chem. 9 (2001) 2969-2978
44. Rutz S., and Scheffold A. Towards in vivo application of RNA interference: New toys, old problems. Arthritis Res. Ther. 6 (2004) 78-85
45. Schiffelers R.M., Woodle M.C., and Scaria P. Pharmaceutical prospects for RNA interference. Pharm. Res. 21 (2004) 1-7
46. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., and Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
47. Schiffelers R.M., Xu J., Storm G., Woodle M.C., and Scaria P.V. Effects of treatment with small interferring RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis & Rheumatism 52 (2005) 1314-1318
48. Semizarov D., Frost L., Sarthy A., Kroeger P., Halbert D.N., and Fesik S.W. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA 100 (2003) 6347-6352
49. Sen A., Steele R., Ghosh A.K., Basu A., Ray R., and Ray R.B. Inhibition of hepatitis C virus protein expression by RNA interference. Virus Res. 96 (2003) 27-35
50. Shishkina G.T., Kalinina T.S., and Dygalo N.N. Attenuation of alpha (2A)-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood. Neuroscience 129 (2004) 521-528
51. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5 (2003) 834-839
52. Song E., Lee S.K., Wang J., Inee N., Ouyang N., Min J., Chen J., Shankar P., and Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitism. Nature Med. 9 (2003) 347-351
53. Sorensen D.R., Leirdal M., and Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 4 (2003) 761-766 327
54. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., and Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178
55. Spagnou S., Miller A.D., and Keller M. Lipidic carriers of siRNA: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43 (2004) 13348-13356
56. Thakker D.R., Natt F., Husken D., Maier R., Muller M., van der Putten H., Hoyer D., and Cryan J.F. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using non-viral RNA interference. Proc. Natl. Acad. Sci. USA 101 (2004) 17270-17275
57. Tiscornia G., Singer O., Ikawa M., and Verma I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA 100 (2003) 1844-1848
58. Tompkins S.M., Lo C.Y., Tumpey T.M., and Epstein S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101 (2004) 8682-8686
59. Walker G.F., Fella C., Pelisek J., Fahrmeir J., Boeckle S., Ogris M., and Wagner E. Toward synthetic viruses: Endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther. 11 3 (2005) 418-425
60. Woodle M.C., Scaria P., Ganesh S., Subramanian K., Titmas R., Cheng C., Yang J., Pan Y., Weng K., Gu C., and Torkelson S. Sterically stabilized polyplex: Ligand-mediated activity. J. Control. Release 74 (2001) 309-311
61. Xia H., Mao Q., Paulson H.L., Davidson B.L., and Xia H. SiRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnol. 20 (2002) 1006-1010
62. Xie F.Y., Liu Y., Xu J., Tang Q.Q., Scaria P.V., Zhou Q., Woodle M.C., and Lu P.Y. Delivering sirna to animal disease models for validation of novel drug targets in vivo. PharmaGenomics July/August (2004) 28-38
63. Zender L., Hutker S., Liedtke C., Tillmann H.L., Zender S., Mundt B., Waltemathe M., Gosling T., Flemming P., Malek N.P., Trautwein C., Manns M.P., Kuhnel F., and Kubicka S. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA 100 (2003) 7797-7802
64. Zhang X., Shan P., Jiang D., Noble P.W., Abraham N.G., Kappas A., and Lee P.J. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279 (2003) 10677-10684